Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Baxter

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR SOLODYN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Solodyn

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00473083 ↗ Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer Completed Hoffmann-La Roche Phase 2 2009-01-01 The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT00473083 ↗ Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer Completed British Columbia Cancer Agency Phase 2 2009-01-01 The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT01048983 ↗ Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) Withdrawn National Cancer Institute (NCI) Phase 1/Phase 2 1969-12-31 The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Solodyn

Condition Name

Condition Name for Solodyn
Intervention Trials
Myeloma 2
Head And Neck Cancer 2
Lung Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Solodyn
Intervention Trials
Lung Neoplasms 4
Carcinoma, Non-Small-Cell Lung 3
Neoplasms, Plasma Cell 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Solodyn

Trials by Country

Trials by Country for Solodyn
Location Trials
United States 30
Germany 4
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Solodyn
Location Trials
Texas 11
Michigan 2
Massachusetts 2
North Carolina 2
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Solodyn

Clinical Trial Phase

Clinical Trial Phase for Solodyn
Clinical Trial Phase Trials
Phase 4 2
Phase 2 12
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Solodyn
Clinical Trial Phase Trials
Completed 11
Active, not recruiting 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Solodyn

Sponsor Name

Sponsor Name for Solodyn
Sponsor Trials
M.D. Anderson Cancer Center 11
National Cancer Institute (NCI) 10
Hoffmann-La Roche 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Solodyn
Sponsor Trials
Other 25
NIH 11
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Baxter
Boehringer Ingelheim
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.